In addition to our study of COVID-19 prevention, we are aggregating and publishing treatment protocols and outcomes from physicians across the country using hydroxychloroquine (HCQ) alone or in combination therapy to combat COVID-19.


Raoult / Gautret et al. Treatment Protocol (March 2020)

NOT MEDICAL ADVICE. APPROPRIATE MEDICAL PROFESSIONALS MUST BE CONSULTED FOR EACH SPECIFIC SITUATION.

  • Adult COVID-19 positive subjects without history of retinopathy, QT prolongation, G6PD deficiency and/or known allergy to hydroxychoroquine, chloroquine or azithromycin. Please review Raoult / Gautret et al. for a complete list of inclusion and exclusion criteria.
  • Participation required written informed signed consent.
  • Hydroxychloroquine sulfate 200mg, three times per day for 10 days
  • Azithromycin 500mg day 1 followed by 250mg per day for days 2-5

NOT MEDICAL ADVICE. APPROPRIATE MEDICAL PROFESSIONALS MUST BE CONSULTED FOR EACH SPECIFIC SITUATION.


Help fight COVID-19: Share your results!

If you're a licensed medical professional treating / have treated COVID-19 positive patients with HCQ in your treatment protocol, we encourage you to share your results.

Once submitted, the results may appear in 4 - 12 hours after we've done a data sanity check.

Click here to submit (for medical professionals only)

As our way of saying thank you for joining this initiative, all contributors will have the option to be publicly recognized in any publications.


Browse submissions

Coming soon to the public. Medical doctors who submitted valid treatment data will have first access.


Disclaimer: This page is intended as reference for medical professionals only, as generated exclusively by medical professionals. The parties involved with covidtrial.io do not make and expressly disclaim all representations and warranties, express, implied, statutory or otherwise, whatsoever, including, but not limited to: (i) warranties of merchantability, fitness for a particular purpose, suitability, usage, title or noninfringement; (ii) that the contents are free from error; and (iii) that such contents will not infringe third-party rights. The parties shall have no liability for damages of any kind arising out of the use, reference to, or reliance on this white paper or any of the content contained herein, even if advised of the possibility of such damages. In no event will the authors and or its affiliates be liable to any person or entity for any damages, losses, liabilities, costs or expenses of any kind, whether direct or indirect, consequential, compensatory, incidental, actual, exemplary, punitive or special for the use of, reference to, or reliance on this white paper or any of the content contained herein, including, without limitation, any loss of business, revenues, profits, data, use, goodwill or other intangible losses.

Copyright. All Rights Reserved.